Physician profile
Joseph B Luttrell
NPI 1902901424
$5,728.72
in general payments reported to CMS, 2019-2025
32 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $589 · 2021: $702 · 2022: $756 · 2023: $995 · 2024: $789 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Education: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.73 |
| Education | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,121.59 | 2019-2025 | |
| Pfizer INC. | $834.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $589.19 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $364.68 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $309.37 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $210.66 | 2019-2025 | |
| Celltrion USA INC. | $150.88 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $148.98 | 2020-2023 | |
| Ardelyx, INC. | $124.31 | 2023-2025 | Ibsrela |
| Intra-Sana Laboratories | $120.52 | 2021-2022 | |
| Madrigal Pharmaceuticals | $114.75 | 2025 | Rezdiffra |
| Celgene Corporation | $74.78 | 2022-2024 | Zeposia |
| Endogastric Solutions, INC | $64.33 | 2022 | |
| Redhill Biopharma INC. | $54.59 | 2020 | |
| Mallinckrodt Hospital Products INC. | $41.32 | 2023-2024 | Terlivaz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.54 | 2025 | Wegovy |
| Evoke Pharma, INC. | $34.01 | 2022-2023 | Gimoti |
| Aimmune Therapeutics, INC. | $33.07 | 2024-2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $32.67 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $32.48 | 2019-2025 | |
| Boston Scientific Corporation | $29.61 | 2020-2021 | |
| Daiichi Sankyo INC. | $28.85 | 2022 | |
| Qol Medical, LLC | $28.77 | 2025 | Sucraid |
| Ucb, INC. | $23.30 | 2019 | |
| Genzyme Corporation | $23.23 | 2023 | |
| Exact Sciences Corporation | $18.38 | 2023 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $16.11 | 2023 | |
| Amgen INC. | $16.07 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $14.54 | 2024 | Dificid |
| Ferring Pharmaceuticals INC. | $13.20 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $11.95 | 2020 | |
| Organon LLC | $9.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Luttrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.